Drug Formulation Market Size to Grow US$ 2.95 Trillion By 2032

The global drug formulation market size was approximate at US$ 1.64  trillion in 2022 and is anticipated to grow US$ 2.95 trillion by 2032, registering a compound annual growth rate of 6.05% from 2023 to 2032.

The drug formulation market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the drug formulation market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2032.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2023 g0066ztr to 2032. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the drug formulation report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the drug formulation market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2561

Drug Formulation Market  Report Scope 

Also read: Humanoid Robot Market Size to Grow US$ 28.66 Billion By 2032

Research Approach

The comprehensive report on the global drug formulation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global drug formulation market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

• Bristol-Myers Squibb
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• 3M Company
• Bayer AG
• Teva Pharmaceuticals Industries Ltd.
• Amgen, Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Boston

Drug Formulation Market  Segmentations

By Formulation

• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations

By Routes of Administration

• Oral
• Topical
• Parenteral
• Inhalations
• Other Routes of Administration

By Therapy Area

• Cardiovascular Diseases (CVDs)
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Other Diseases

By End-User

• Retail
• Non-retail

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Formulation Market 

5.1. COVID-19 Landscape: Drug Formulation Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Formulation Market, By Formulation

8.1. Drug Formulation Market, by Formulation, 2023-2032

8.1.1. Tablets

8.1.1.1. Market Revenue and Forecast (2023-2032)

8.1.2. Capsules

8.1.2.1. Market Revenue and Forecast (2023-2032)

8.1.3. Injectable

8.1.3.1. Market Revenue and Forecast (2023-2032)

8.1.4. Sprays

8.1.4.1. Market Revenue and Forecast (2023-2032)

8.1.5. Suspensions

8.1.5.1. Market Revenue and Forecast (2023-2032)

8.1.6. Powders

8.1.6.1. Market Revenue and Forecast (2023-2032)

8.1.7. Other Formulations

8.1.7.1. Market Revenue and Forecast (2023-2032)

Chapter 9. Global Drug Formulation Market, By Routes of Administration

9.1. Drug Formulation Market, by Routes of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2023-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2023-2032)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2023-2032)

9.1.4. Inhalations

9.1.4.1. Market Revenue and Forecast (2023-2032)

9.1.5. Other Routes of Administration

9.1.5.1. Market Revenue and Forecast (2023-2032)

Chapter 10. Global Drug Formulation Market, By Therapy Area 

10.1. Drug Formulation Market, by Therapy Area, 2023-2032

10.1.1. Cardiovascular Diseases (CVDs)

10.1.1.1. Market Revenue and Forecast (2023-2032)

10.1.2. Pain

10.1.2.1. Market Revenue and Forecast (2023-2032)

10.1.3. Diabetes

10.1.3.1. Market Revenue and Forecast (2023-2032)

10.1.4. Cancer

10.1.4.1. Market Revenue and Forecast (2023-2032)

10.1.5. Respiratory Diseases

10.1.5.1. Market Revenue and Forecast (2023-2032)

10.1.6. Other Diseases

10.1.6.1. Market Revenue and Forecast (2023-2032)

Chapter 11. Global Drug Formulation Market, By End-User 

11.1. Drug Formulation Market, by End-User, 2023-2032

11.1.1. Retail

11.1.1.1. Market Revenue and Forecast (2023-2032)

11.1.2. Non-retail

11.1.2.1. Market Revenue and Forecast (2023-2032)

Chapter 12. Global Drug Formulation Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.4. Market Revenue and Forecast, by End-User (2023-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2023-2032)

Chapter 13. Company Profiles

13.1. Bristol-Myers Squibb

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eli Lilly and Company

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Gilead Sciences, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Merck & Co., Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Novartis AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Pfizer Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. AbbVie Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Boehringer Ingelheim International GmbH

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. F. Hoffmann-La Roche AG

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global drug formulation market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug formulation are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com